Hair and scalp protocols
Exosome and small-molecule supply for hair and scalp protocols
ExaVeyra supplies research-use exosome formats to licensed practices, refers prescribers to a 503A compounding pharmacy that prepares hair and scalp formulations against an individual prescription where it holds a non-resident license, and publishes the literature and the FDA position on each formulation class so that a practice can read both before it applies for an account. This page is the door onto all of it: the blog series, the peer-reviewed science pages, the product category, and the supply pages by region and by state.
Written for licensed practitioners and practice operators. The FDA has not approved GHK-Cu or any exosome product for hair loss or any form of alopecia, and compounded medications are not FDA-approved finished drug products; every page in the program says so beside its own material.
Two product regimes, and they never mix
| Product class | Ships to | Regime |
|---|---|---|
| Research-use exosome formats | Every state and Puerto Rico | Research Use Only. Lot characterisation and a certificate of analysis available on request. No exosome product is FDA-approved. |
| Compounded 503A formulations | Where the 503A pharmacy partner holds a non-resident license | Prescription products prepared for one patient. Not FDA-approved finished drug products. Listed in the hair and scalp formulations category. |
The evidence, one formulation class at a time
4 of 9 references published, with the study design labelled beside every citation.
The Hair Follicle Cycle and the Levers a Protocol Acts On
In review
Finasteride: Mechanism, Approved Label, and Topical Literature
The oral label, the topical literature, and the FDA alert.
Minoxidil, Minoxidil Sulfate, and Follicular Sulfotransferase
The prodrug, the enzyme, and the combinations.
GHK-Cu in Follicle and Dermal Papilla Research
Follicle culture, animal models, and the regulatory position.
Extracellular Vesicles and Dermal Papilla Signalling
The human evidence to date, the registry, and the FDA communications.
Ketoconazole and Azelaic Acid in Scalp Research
In review
Vitamin D, Biotin, Thyroid and Sex Steroids in Hair Shedding
In review
Microneedling, PRP and Topical Anaesthesia in Scalp Protocols
In review
FDA Communications Relevant to Hair Products
In review
The ExaBlog series
10 articles in the Hair Restoration Research category, from the landscape overview to a deep dive per component.
- Scalp Microneedling and Topical Anaesthesia: The Procedure Side of a Hair Protocol
12 min read · English and Spanish
- Thyroid, Estrogens and Androgens: The Hormonal Context of Shedding in an Optimization Practice
12 min read · English and Spanish
- Biotin, Vitamin D and B12: Where Deficiency Matters, Where It Does Not, and the Lab Notice Practices Miss
11 min read · English and Spanish
- Thymosin Beta-4, TB-500, and Follicle Stem Cells: An Animal-Data Review
11 min read · English and Spanish
- Ketoconazole and Azelaic Acid as Scalp Adjuncts: Two Side Doors into the Hair Literature
11 min read · English and Spanish
- Minoxidil Is a Prodrug: Sulfotransferase, Tretinoin, and the Responder Question
12 min read · English and Spanish
- Finasteride and 5-Alpha-Reductase: The Oral Label, the Topical Literature, and the FDA Alert
14 min read · English and Spanish
- GHK-Cu and the Hair Follicle: What a Tripeptide-Copper Complex Does in the Literature
12 min read · English and Spanish
- Hair and Scalp Protocol Components in 2026: What the Literature Supports for Each Formulation Class
16 min read · English and Spanish
- Exosomes for Hair Restoration: What the Research Says
12 min read
Supply by region and by state
Each regional page answers what a practice in that place can source, how cold-chain material arrives, and where the state law questions are answered. Compounded availability on every page is read from the same registry as the coverage table, so the pages cannot disagree with each other.
States where compounded formulations ship today
Program questions
- Are GHK-Cu or exosome products FDA-approved for hair loss or any form of alopecia?
- No. The FDA has not approved GHK-Cu or any exosome product for hair loss or any form of alopecia, and there are no FDA-approved exosome products of any kind. Oral one-milligram finasteride and topical minoxidil are the two FDA-approved actives in this area; compounded formulations that contain them are not FDA-approved finished drug products and are prepared under section 503A against an individual prescription. The evidence pages state the regulatory position for each formulation class beside its literature.
- What does ExaVeyra supply for a hair and scalp protocol, and under which regime?
- Two product classes that never mix. Research-use exosome material, characterised per lot with a certificate of analysis available on request, ships to licensed practices in every state and Puerto Rico. Compounded 503A preparations, the topical solutions, creams and oral capsules listed in the hair and scalp formulations category, are prepared to an individual prescription by the 503A pharmacy partner and dispensed by that pharmacy where it holds a non-resident pharmacy license; the coverage page and the regional pages state where that is.
- Who is the program written for?
- Licensed practitioners and practice operators. The blog series is written to be read; the science pages are written to be cited, with the study design labelled beside every reference; the regional and state pages answer what a practice in a given place can source and how it arrives. None of it is written for patients, and ExaVeyra takes no part in any diagnosis, treatment decision or plan of care.
- Does ExaVeyra supply controlled substances?
- No. Testosterone and the other anabolic agents that appear in the hormonal-context article are discussed there because the literature connects them to shedding, and the article says so; ExaVeyra Sciences does not supply controlled substances.
Nothing on this page has been reviewed or approved by the FDA. There are no FDA-approved exosome products. Exosome material distributed by ExaVeyra Sciences is supplied for Research Use Only, for medical, molecular biology, and biochemistry research applications, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved finished drug products; they are prepared under section 503A against a prescription for an individual patient, dispensed by the pharmacy, and are prescription products rather than research-use-only material.
This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. The FDA has not approved GHK-Cu or any exosome product for hair loss or any form of alopecia. Compounded medications are not FDA-approved; they are prepared by a licensed 503A compounding pharmacy for an individual patient against that patient’s prescription, and they are supplied to NPI-verified licensed practitioners only. Where this page discusses an FDA-approved active such as oral finasteride or topical minoxidil, the approved product’s labeling governs and nothing here modifies it. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. ExaVeyra Sciences does not supply controlled substances. Findings described on this page are attributed to the peer-reviewed literature and to the agencies cited, and a citation establishes that a question was studied, not that any product is suitable for a given patient. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here. Exosome material is supplied for Research Use Only. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome.
Reference only. Not legal or medical advice.
The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Read the full disclaimer
ExaVeyra Sciences publishes these guides as a reference for licensed practitioners. They summarize publicly available federal and state requirements as those requirements read on the review date shown above. The content is provided for general informational purposes only and does not constitute legal, medical, or regulatory advice, and it does not establish that any particular product or practice is compliant.
No attorney-client relationship, and no professional or clinical relationship of any kind, is created by accessing these materials. ExaVeyra Sciences is a supplier of research-use materials. It is not a law firm, it is not a regulatory consultant, and it takes no part in any diagnosis, treatment decision, or plan of care. Each practitioner is responsible for retaining their own legal counsel and for determining, with that counsel and the applicable state licensing boards, how the requirements described here apply to the services, staffing, and structure of their own practice.
Statutes, regulations, board rules, and agency positions are subject to amendment, supersession, and reinterpretation. ExaVeyra Sciences makes no representation or warranty as to the accuracy, completeness, timeliness, or applicability of this content to any particular practice. Citations and links to third-party sources are provided for convenience only and do not constitute an endorsement of their content.
The practitioner and the practice are solely responsible for compliance with all applicable licensing, scope of practice, supervision, ownership, facility, recordkeeping, and tax requirements, and for all clinical decisions, including the suitability of any material for a given patient. To the fullest extent permitted by law, ExaVeyra Sciences disclaims all liability for any action taken or not taken in reliance on this content.